Soleus Capital Management L.P. Boosts Position in Pharvaris (NASDAQ:PHVS)

Soleus Capital Management L.P. raised its position in Pharvaris (NASDAQ:PHVS) by 36.2% during the fourth quarter, Holdings Channel reports. The fund owned 814,652 shares of the company’s stock after acquiring an additional 216,483 shares during the period. Soleus Capital Management L.P.’s holdings in Pharvaris were worth $15,617,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Point72 Asset Management L.P. purchased a new stake in shares of Pharvaris during the 4th quarter valued at about $152,000. Octagon Capital Advisors LP boosted its holdings in shares of Pharvaris by 25.4% in the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock worth $14,914,000 after buying an additional 157,530 shares during the last quarter. Deutsche Bank AG grew its position in Pharvaris by 13.0% during the fourth quarter. Deutsche Bank AG now owns 18,168 shares of the company’s stock valued at $348,000 after buying an additional 2,087 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Pharvaris during the fourth quarter valued at approximately $64,000. Finally, Bank of America Corp DE increased its holdings in Pharvaris by 205,286.7% during the fourth quarter. Bank of America Corp DE now owns 30,808 shares of the company’s stock valued at $591,000 after buying an additional 30,793 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on PHVS. Cantor Fitzgerald dropped their price target on shares of Pharvaris from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 14th. JMP Securities raised their target price on Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a report on Friday, January 31st.

Pharvaris Stock Up 4.1%

PHVS stock opened at $16.56 on Monday. The business’s 50-day moving average price is $15.38 and its 200-day moving average price is $17.58. The stock has a market cap of $865.92 million, a P/E ratio of -5.91 and a beta of -2.85. Pharvaris has a twelve month low of $11.51 and a twelve month high of $25.50.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.09). On average, equities research analysts expect that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.